<?xml version="1.0" encoding="UTF-8"?>
<!--REG30PARAB V1.0 (01-06-2026)-->
<xbrli:xbrl xmlns:in-capmkt="http://www.sebi.gov.in/xbrl/2026-04-30/in-capmkt" xmlns:in-capmkt-ent="http://www.sebi.gov.in/xbrl/Regulation_30_Para_B_Of_Part_A_Of_Schedule_III/2026-04-30/in-capmkt/in-capmkt-ent" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:in-capmkt-types="http://www.sebi.gov.in/xbrl/2026-04-30/in-capmkt-types" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.w3.org/1999/xlink"><link:schemaRef xlink:type="simple" xlink:href="in-capmkt-ent-2026-04-30.xsd"/><xbrli:context id="MainI"><xbrli:entity><xbrli:identifier scheme="http://www.sebi.gov.in/in-capmkt/ScripCode">524558</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="INR"><xbrli:measure>iso4217:INR</xbrli:measure></xbrli:unit><in-capmkt:NSESymbol contextRef="MainI">NEULANDLAB</in-capmkt:NSESymbol><in-capmkt:NameOfTheCompany contextRef="MainI">NEULAND LABORATORIES LIMITED</in-capmkt:NameOfTheCompany><in-capmkt:ScripCode contextRef="MainI">524558</in-capmkt:ScripCode><in-capmkt:MSEISymbol contextRef="MainI">NOTLISTED</in-capmkt:MSEISymbol><in-capmkt:ISIN contextRef="MainI">INE794A01010</in-capmkt:ISIN><in-capmkt:TypeOfEventAsPerRegulation30ParaBOfPartAOfScheduleIII contextRef="MainI">Giving of guarantees or indemnity (Sub-para 11-Para B)</in-capmkt:TypeOfEventAsPerRegulation30ParaBOfPartAOfScheduleIII><in-capmkt:TypeOfAnnouncementAsPerRegulation30ParaBOfPartAOfScheduleIII contextRef="MainI">New</in-capmkt:TypeOfAnnouncementAsPerRegulation30ParaBOfPartAOfScheduleIII><in-capmkt:WhetherEventOrInformationDisclosedIsAnOutcomeOfTheBoardMeeting contextRef="MainI">true</in-capmkt:WhetherEventOrInformationDisclosedIsAnOutcomeOfTheBoardMeeting><in-capmkt:DateOfBoardMeeting contextRef="MainI">2026-08-05</in-capmkt:DateOfBoardMeeting><in-capmkt:StartTimeOfTheMeeting contextRef="MainI">10:00:00</in-capmkt:StartTimeOfTheMeeting><in-capmkt:EndTimeOfTheMeeting contextRef="MainI">15:42:00</in-capmkt:EndTimeOfTheMeeting><in-capmkt:DateOfReport contextRef="MainI">2026-08-05</in-capmkt:DateOfReport><in-capmkt:EventTypeOfGuaranteeOrIndemnityOrSurety contextRef="MainI">Giving guarantees</in-capmkt:EventTypeOfGuaranteeOrIndemnityOrSurety><in-capmkt:NameOfPartyForWhomGuaranteeOrIndemnityOrSuretyWasGiven contextRef="MainI">Gland Pharma Limited</in-capmkt:NameOfPartyForWhomGuaranteeOrIndemnityOrSuretyWasGiven><in-capmkt:WhetherThePromoterOrPromoterGroupOrGroupCompaniesHaveAnyInterestInGuaranteeOrIndemnityOrSuretyTransaction contextRef="MainI">false</in-capmkt:WhetherThePromoterOrPromoterGroupOrGroupCompaniesHaveAnyInterestInGuaranteeOrIndemnityOrSuretyTransaction><in-capmkt:BriefDetailsOfGuaranteeOrIndemnityOrSurety contextRef="MainI">The Company will be executing an irrevocable, unconditional and continuing Corporate Guarantee of Rs. 40 crores in favour of Gland Pharma Limited in connection with the obligations of the Company under a Loan Licence Agreement to be entered into with Gland Pharma Limited.

Under the Loan Licence Agreement, Gland Pharma Limited has agreed to establish dedicated manufacturing capacity and incur capital expenditure for the manufacture of certain products. The Corporate Guarantee secures the due payment and performance by the Company of its obligations under the Loan Licence Agreement.</in-capmkt:BriefDetailsOfGuaranteeOrIndemnityOrSurety><in-capmkt:SignificantTermsAndConditionsOfGuaranteeOrIndemnityOrSurety contextRef="MainI">The Company will be executing an irrevocable, unconditional and continuing Corporate Guarantee of Rs. 40 crores in favour of Gland Pharma Limited in connection with the obligations of the Company under a Loan Licence Agreement to be entered into with Gland Pharma Limited.

Under the Loan Licence Agreement, Gland Pharma Limited has agreed to establish dedicated manufacturing capacity and incur capital expenditure for the manufacture of certain products. The Corporate Guarantee secures the due payment and performance by the Company of its obligations under the Loan Licence Agreement.</in-capmkt:SignificantTermsAndConditionsOfGuaranteeOrIndemnityOrSurety><in-capmkt:AmountOfGuaranteeOrIndemnityOrSurety contextRef="MainI" unitRef="INR" decimals="0">400000000</in-capmkt:AmountOfGuaranteeOrIndemnityOrSurety><in-capmkt:ImpactOfGuaranteeOrIndemnityOrSuretyOnListedEntity contextRef="MainI">There is no immediate impact on the financials of the Company. The corporate guarantee represents a contingent liability for the Company.</in-capmkt:ImpactOfGuaranteeOrIndemnityOrSuretyOnListedEntity></xbrli:xbrl>
